Treatments targeting either of the two main pathological hallmarks of the AD brain, amyloid-beta (Aβ) and tau aggregation, have been mostly unsuccessful, driving the search for alternative treatable causative agents of AD. This evidence concerns the gene MAPT and Alzheimer disease.